The Impact of Obesity on Inflammatory Bowel Disease
Abstract
:1. Background
2. Prevalence of Obesity in IBD
3. Obesity and IBD Pathogenesis
3.1. The Adipose Tissue
3.2. Creeping Fat…Good and Bad
3.3. Adipocytes
4. Obesity and Disease Course
5. Obesity and Disease Management
6. Obesity and Thiopurines
7. Obesity and Anti-TNF Therapy
8. Obesity in IBD-Related Surgery
9. Obesity Treatments and Outcomes in IBD
9.1. GLP1-Based Therapy
9.2. Bariatric Surgery
10. Physical Exercise as a Treatment for Patients with IBD
11. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- World Obesity Federation. World Obesity Atlas. Available online: https://data.worldobesity.org/publications/?cat=19 (accessed on 5 October 2023).
- Obesity and Overweight. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 10 October 2023).
- Welfare AIoHa. Australia’s Health 2018. Available online: https://www.aihw.gov.au/reports/australias-health/australias-health-2018/contents/burden-of-disease-scenario-modelling/overweight-obesity (accessed on 5 October 2023).
- Hall, K.D. Did the Food Environment Cause the Obesity Epidemic? Obesity 2018, 26, 11–13. [Google Scholar] [CrossRef] [PubMed]
- Touvier, M.; Louzada, M.L.d.C.; Mozaffarian, D.; Baker, P.; Juul, F.; Srour, B. Ultra-processed foods and cardiometabolic health: Public health policies to reduce consumption cannot wait. BMJ 2023, 383, e075294. [Google Scholar] [CrossRef]
- Beck, S.J. Stoma issues in the obese patient. Clin. Colon Rectal Surg. 2011, 24, 259–262. [Google Scholar] [CrossRef] [PubMed]
- Stępień, M.; Stępień, A.; Wlazeł, R.N.; Paradowski, M.; Banach, M.; Rysz, J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: A comparative pilot study. Lipids Health Dis. 2014, 13, 29. [Google Scholar] [CrossRef] [PubMed]
- Ellulu, M.S.; Patimah, I.; Khaza’ai, H.; Rahmat, A.; Abed, Y. Obesity and inflammation: The linking mechanism and the complications. Arch. Med. Sci. 2017, 13, 851–863. [Google Scholar] [CrossRef] [PubMed]
- Corvera, S. Cellular Heterogeneity in Adipose Tissues. Annu. Rev. Physiol. 2021, 83, 257–278. [Google Scholar] [CrossRef] [PubMed]
- Ananthakrishnan, A.N.; Bernstein, C.N.; Iliopoulos, D.; Macpherson, A.; Neurath, M.F.; Ali, R.A.R.; Vavricka, S.R.; Fiocchi, C. Environmental triggers in IBD: A review of progress and evidence. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 39–49. [Google Scholar] [CrossRef]
- Kaplan, G.G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 720–727. [Google Scholar] [CrossRef]
- Alatab, S.; Sepanlou, S.G.; Ikuta, K.; Vahedi, H.; Bisignano, C.; Safiri, S.; Sadeghi, A.; Nixon, M.R.; Abdoli, A.; Abolhassani, H.; et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020, 5, 17–30. [Google Scholar] [CrossRef]
- Singh, S.; Dulai, P.S.; Zarrinpar, A.; Ramamoorthy, S.; Sandborn, W.J. Obesity in IBD: Epidemiology, pathogenesis, disease course and treatment outcomes. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 110–121. [Google Scholar] [CrossRef]
- Peyrin-Biroulet, L.; Gonzalez, F.; Dubuquoy, L.; Rousseaux, C.; Dubuquoy, C.; Decourcelle, C.; Saudemont, A.; Tachon, M.; Béclin, E.; Odou, M.F.; et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease. Gut 2012, 61, 78–85. [Google Scholar] [CrossRef] [PubMed]
- Desreumaux, P.; Ernst, O.; Geboes, K.; Gambiez, L.; Berrebi, D.; Müller-Alouf, H.; Hafraoui, S.; Emilie, D.; Ectors, N.; Peuchmaur, M.; et al. Inflammatory alterations in mesenteric adipose tissue in Crohn’s disease. Gastroenterology 1999, 117, 73–81. [Google Scholar] [CrossRef] [PubMed]
- Batra, A.; Zeitz, M.; Siegmund, B. Adipokine signaling in inflammatory bowel disease. Inflamm. Bowel Dis. 2009, 15, 1897–1905. [Google Scholar] [CrossRef] [PubMed]
- Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Barkema, H.W.; et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142, 46–54.e42, quiz e30. [Google Scholar] [CrossRef] [PubMed]
- Flores, A.; Burstein, E.; Cipher, D.J.; Feagins, L.A. Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. Dig. Dis. Sci. 2015, 60, 2436–2445. [Google Scholar] [CrossRef] [PubMed]
- Seminerio, J.L.; Koutroubakis, I.E.; Ramos-Rivers, C.; Hashash, J.G.; Dudekula, A.; Regueiro, M.; Baidoo, L.; Barrie, A.; Swoger, J.; Schwartz, M.; et al. Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2015, 21, 2857–2863. [Google Scholar] [CrossRef] [PubMed]
- Long, M.D.; Crandall, W.V.; Leibowitz, I.H.; Duffy, L.; del Rosario, F.; Kim, S.C.; Integlia, M.J.; Berman, J.; Grunow, J.; Colletti, R.B.; et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17, 2162–2168. [Google Scholar] [CrossRef] [PubMed]
- Khalili, H.; Ananthakrishnan, A.N.; Konijeti, G.G.; Higuchi, L.M.; Fuchs, C.S.; Richter, J.M.; Chan, A.T. Measures of obesity and risk of Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis. 2015, 21, 361–368. [Google Scholar] [CrossRef]
- Jensen, C.B.; Ängquist, L.H.; Mendall, M.A.; Sørensen, T.I.A.; Baker, J.L.; Jess, T. Childhood body mass index and risk of inflammatory bowel disease in adulthood: A population-based cohort study. Am. J. Gastroenterol. 2018, 113, 694–701. [Google Scholar] [CrossRef]
- Chan, S.S.; Luben, R.; Olsen, A.; Tjonneland, A.; Kaaks, R.; Teucher, B.; Lindgren, S.; Grip, O.; Key, T.; Crowe, F.L.; et al. Body mass index and the risk for Crohn’s disease and ulcerative colitis: Data from a European Prospective Cohort Study (The IBD in EPIC Study). Am. J. Gastroenterol. 2013, 108, 575–582. [Google Scholar] [CrossRef]
- He, Z.; Fu, T.; Lu, S.; Sun, Y.; Zhang, Y.; Shi, W.; Li, Z.; Deng, M.; Chen, J.; Bai, Y. Adiposity as a risk factor for inflammatory bowel disease and the mediating effect of metabolic and inflammatory status: A population-based cohort study. United Eur. Gastroenterol. J. 2023. Early View. [Google Scholar] [CrossRef]
- Harpsøe, M.C.; Basit, S.; Andersson, M.; Nielsen, N.M.; Frisch, M.; Wohlfahrt, J.; Nohr, E.A.; Linneberg, A.; Jess, T. Body mass index and risk of autoimmune diseases: A study within the Danish National Birth Cohort. Int. J. Epidemiol. 2014, 43, 843–855. [Google Scholar] [CrossRef]
- Pringle, P.L.; Stewart, K.O.; Peloquin, J.M.; Sturgeon, H.C.; Nguyen, D.; Sauk, J.; Garber, J.J.; Yajnik, V.; Ananthakrishnan, A.N.; Chan, A.T.; et al. Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn’s Disease. Inflamm. Bowel Dis. 2015, 21, 2304–2310. [Google Scholar] [CrossRef] [PubMed]
- Hass, D.J.; Brensinger, C.M.; Lewis, J.D.; Lichtenstein, G.R. The impact of increased body mass index on the clinical course of Crohn’s disease. Clin. Gastroenterol. Hepatol. 2006, 4, 482–488. [Google Scholar] [CrossRef] [PubMed]
- Hemminki, K.; Li, X.; Sundquist, J.; Sundquist, K. Risk of asthma and autoimmune diseases and related conditions in patients hospitalized for obesity. Ann. Med. 2012, 44, 289–295. [Google Scholar] [CrossRef] [PubMed]
- Deurenberg, P.; Deurenberg-Yap, M.; Guricci, S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes. Rev. 2002, 3, 141–146. [Google Scholar] [CrossRef]
- Avery, J.; Taylor, A.; DalGrande, E. Measuring BMI in an Aboriginal population survey: Who are the non-responders? Aust. Indig. Health 2015, 15, 1–12. [Google Scholar]
- Gadekar, T.; Dudeja, P.; Basu, I.; Vashisht, S.; Mukherji, S. Correlation of visceral body fat with waist-hip ratio, waist circumference and body mass index in healthy adults: A cross sectional study. Med. J. Armed Forces India 2020, 76, 41–46. [Google Scholar] [CrossRef]
- Chan, D.C.; Watts, G.F.; Barrett, P.H.R.; Burke, V. Waist circumference, waist-to-hip ratio and body mass index as predictors of adipose tissue compartments in men. QJM An Int. J. Med. 2003, 96, 441–447. [Google Scholar] [CrossRef]
- Borruel, S.; Moltó, J.F.; Alpañés, M.; Fernández-Durán, E.; Álvarez-Blasco, F.; Luque-Ramírez, M.; Escobar-Morreale, H.F. Surrogate Markers of Visceral Adiposity in Young Adults: Waist Circumference and Body Mass Index Are More Accurate than Waist Hip Ratio, Model of Adipose Distribution and Visceral Adiposity Index. PLoS ONE 2014, 9, e114112. [Google Scholar] [CrossRef]
- Murata, H.; Yagi, T.; Midorikawa, T.; Torii, S.; Takai, E.; Taguchi, M. Comparison between DXA and MRI for the Visceral Fat Assessment in Athletes. Int. J. Sports Med. 2022, 43, 625–631. [Google Scholar] [CrossRef] [PubMed]
- Ibrahim, M.M. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes. Rev. 2010, 11, 11–18. [Google Scholar] [CrossRef] [PubMed]
- Sakers, A.; De Siqueira, M.K.; Seale, P.; Villanueva, C.J. Adipose-tissue plasticity in health and disease. Cell 2022, 185, 419–446. [Google Scholar] [CrossRef] [PubMed]
- Vishvanath, L.; Gupta, R.K. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. J. Clin. Investig. 2019, 129, 4022–4031. [Google Scholar] [CrossRef] [PubMed]
- Fujisaka, S.; Usui, I.; Ikutani, M.; Aminuddin, A.; Takikawa, A.; Tsuneyama, K.; Mahmood, A.; Goda, N.; Nagai, Y.; Takatsu, K.; et al. Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1α-dependent and HIF-1α-independent manner in obese mice. Diabetologia 2013, 56, 1403–1412. [Google Scholar] [CrossRef] [PubMed]
- Liu, R.; Nikolajczyk, B.S. Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond. Front. Immunol. 2019, 10, 1587. [Google Scholar] [CrossRef] [PubMed]
- Kredel, L.I.; Siegmund, B. Adipose-tissue and intestinal inflammation—visceral obesity and creeping fat. Front. Immunol. 2014, 5, 462. [Google Scholar] [CrossRef] [PubMed]
- Peyrin-Biroulet, L.; Chamaillard, M.; Gonzalez, F.; Beclin, E.; Decourcelle, C.; Antunes, L.; Gay, J.; Neut, C.; Colombel, J.F.; Desreumaux, P. Mesenteric fat in Crohn’s disease: A pathogenetic hallmark or an innocent bystander? Gut 2007, 56, 577–583. [Google Scholar] [CrossRef]
- Drouet, M.; Dubuquoy, L.; Desreumaux, P.; Bertin, B. Visceral fat and gut inflammation. Nutrition 2012, 28, 113–117. [Google Scholar] [CrossRef]
- Fink, C.; Karagiannides, I.; Bakirtzi, K.; Pothoulakis, C. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm. Bowel Dis. 2012, 18, 1550–1557. [Google Scholar] [CrossRef]
- Ha, C.W.Y.; Martin, A.; Sepich-Poore, G.D.; Shi, B.; Wang, Y.; Gouin, K.; Humphrey, G.; Sanders, K.; Ratnayake, Y.; Chan, K.S.L.; et al. Translocation of Viable Gut Microbiota to Mesenteric Adipose Drives Formation of Creeping Fat in Humans. Cell 2020, 183, 666–683. [Google Scholar] [CrossRef]
- Hendrickson, B.A.; Gokhale, R.; Cho, J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 2002, 15, 79–94. [Google Scholar] [CrossRef]
- Mao, R.; Doyon, G.; Gordon, I.O.; Li, J.; Lin, S.; Wang, J.; Le, T.H.N.; Elias, M.; Kurada, S.; Southern, B.; et al. Activated intestinal muscle cells promote preadipocyte migration: A novel mechanism for creeping fat formation in Crohn’s disease. Gut 2022, 71, 55–67. [Google Scholar] [CrossRef]
- Pond, C.M. Adipose tissue, the anatomists’ Cinderella, goes to the ball at last, and meets some influential partners. J. Contin. Med. Educ. 2000, 76, 671–673. [Google Scholar] [CrossRef]
- Charrière, G.; Cousin, B.; Arnaud, E.; André, M.; Bacou, F.; Penicaud, L.; Casteilla, L. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem. 2003, 278, 9850–9855. [Google Scholar] [CrossRef]
- Recinella, L.; Orlando, G.; Ferrante, C.; Chiavaroli, A.; Brunetti, L.; Leone, S. Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. Front. Physiol. 2020, 11, 578966. [Google Scholar] [CrossRef]
- Greuter, T.; Porchet, F.; Braga-Neto, M.B.; Rossel, J.-B.; Biedermann, L.; Schreiner, P.; Scharl, M.; Schoepfer, A.M.; Safroneeva, E.; Straumann, A.; et al. Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. United Eur. Gastroenterol. J. 2020, 8, 1196–1207. [Google Scholar] [CrossRef] [PubMed]
- Weissman, S.; Patel, K.; Kolli, S.; Lipcsey, M.; Qureshi, N.; Elias, S.; Walfish, A.; Swaminath, A.; Feuerstein, J.D. Obesity in Inflammatory Bowel Disease Is Associated with Early Readmissions Characterised by an Increased Systems and Patient-level Burden. J. Crohn’s Colitis 2021, 15, 1807–1815. [Google Scholar] [CrossRef] [PubMed]
- Blain, A.; Cattan, S.; Beaugerie, L.; Carbonnel, F.; Gendre, J.P.; Cosnes, J. Crohn’s disease clinical course and severity in obese patients. Clin. Nutr. 2002, 21, 51–57. [Google Scholar] [CrossRef] [PubMed]
- Dotan, I.; Ron, Y.; Yanai, H.; Becker, S.; Fishman, S.; Yahav, L.; Ben Yehoyada, M.; Mould, D.R. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study. Inflamm. Bowel Dis. 2014, 20, 2247–2259. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.; Eckert, D.; Hyams, J.S.; Mensing, S.; Thakkar, R.B.; Robinson, A.M.; Rosh, J.R.; Ruemmele, F.M.; Awni, W.M. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease: Results from a randomized, multicenter, phase-3 study. Inflamm. Bowel Dis. 2015, 21, 783–792. [Google Scholar] [CrossRef] [PubMed]
- Hanley, M.J.; Abernethy, D.R.; Greenblatt, D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 2010, 49, 71–87. [Google Scholar] [CrossRef] [PubMed]
- Holtmann, M.H.; Krummenauer, F.; Claas, C.; Kremeyer, K.; Lorenz, D.; Rainer, O.; Vogel, I.; Böcker, U.; Böhm, S.; Büning, C.; et al. Significant differences between Crohn’s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: Results from a European multicenter study in 1,176 patients. Dig. Dis. Sci. 2010, 55, 1066–1078. [Google Scholar] [CrossRef] [PubMed]
- Poon, S.S.; Asher, R.; Jackson, R.; Kneebone, A.; Collins, P.; Probert, C.; Dibb, M.; Subramanian, S. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. J. Crohns Colitis 2015, 9, 640–646. [Google Scholar] [CrossRef] [PubMed]
- Harper, J.W.; Sinanan, M.N.; Zisman, T.L. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2013, 19, 2118–2124. [Google Scholar] [CrossRef] [PubMed]
- Bultman, E.; de Haar, C.; van Liere-Baron, A.; Verhoog, H.; West, R.L.; Kuipers, E.J.; Zelinkova, Z.; van der Woude, C.J. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment. Pharmacol. Ther. 2012, 35, 335–341. [Google Scholar] [CrossRef]
- Bhalme, M.; Sharma, A.; Keld, R.; Willert, R.; Campbell, S. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur. J. Gastroenterol. Hepatol. 2013, 25, 543–549. [Google Scholar] [CrossRef]
- Buisson, A.; Nachury, M.; Reymond, M.; Yzet, C.; Wils, P.; Payen, L.; Laugie, M.; Manlay, L.; Mathieu, N.; Pereira, B.; et al. Effectiveness of Switching from Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: The REMSWITCH Study. Clin. Gastroenterol. Hepatol. 2023, 21, 2338–2346.e2333. [Google Scholar] [CrossRef]
- Boutros, M.; Maron, D. Inflammatory bowel disease in the obese patient. Clin. Colon. Rectal Surg. 2011, 24, 244–252. [Google Scholar] [CrossRef]
- Tzatzarakis, E.; Herrle, F.; Reindl, W.; Altmayer, N.; Minas, D.; Kienle, P.; Reissfelder, C.; Sandra-Petrescu, F. Association of ileocolic pedicle division with postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis. BMC Surg. 2021, 21, 426. [Google Scholar] [CrossRef]
- Fazio, V.W.; Delaney, C.J.M.; Kiran, C.P. Chronic ulcerative colitis: Surgical options. Curr. Ther. Colon Rectal Surg. 2005, 2, 211–217. [Google Scholar]
- Church, J.M. The ileal pouch-anal anastomosis in challenging patients: Stretching the limits. Aust. N. Z. J. Surg. 1995, 65, 104–106. [Google Scholar] [CrossRef]
- Dietz, D.W. Postoperative complications. In The ASCRS Textbook of Colon and Rectal Surgery; Wolf, B.G., Fleshman, J.W., Beck, D.E., Pemberton, J.H., Wexner, S.D., Eds.; Springer: New York, NY, USA, 2007; pp. 141–155. [Google Scholar]
- Meguid, M.M.; McIvor, A.; Xenos, L. Creation of a neoabdominal wall to facilitate emergency placement of a terminal ileostomy in a morbidly obese patient. Am. J. Surg. 1997, 173, 298–300. [Google Scholar] [CrossRef] [PubMed]
- Duchesne, J.C.; Wang, Y.Z.; Weintraub, S.L.; Boyle, M.; Hunt, J.P. Stoma complications: A multivariate analysis. Am. Surg. 2002, 68, 961–966, discussion 966. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Zhu, W.; Gong, J.; Zhang, W.; Gu, L.; Guo, Z.; Cao, L.; Shen, B.; Li, N.; Li, J. Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn’s disease. Color. Dis. 2015, 17, 225–234. [Google Scholar] [CrossRef] [PubMed]
- Erhayiem, B.; Dhingsa, R.; Hawkey, C.J.; Subramanian, V. Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn’s disease. Clin. Gastroenterol. Hepatol. 2011, 9, 684–687.e681. [Google Scholar] [CrossRef] [PubMed]
- Maconi, G.; Greco, S.; Duca, P.; Ardizzone, S.; Massari, A.; Cassinotti, A.; Radice, E.; Porro, G.B. Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn’s disease. Inflamm. Bowel Dis. 2008, 14, 1555–1561. [Google Scholar] [CrossRef]
- Coffey, C.J.; Kiernan, M.G.; Sahebally, S.M.; Jarrar, A.; Burke, J.P.; Kiely, P.A.; Shen, B.; Waldron, D.; Peirce, C.; Moloney, M.; et al. Inclusion of the Mesentery in Ileocolic Resection for Crohn’s Disease is Associated with Reduced Surgical Recurrence. J. Crohns Colitis 2018, 12, 1139–1150. [Google Scholar] [CrossRef]
- Alshantti, A.; Hind, D.; Hancock, L.; Brown, S.R. The role of Kono-S anastomosis and mesenteric resection in reducing recurrence after surgery for Crohn’s disease: A systematic review. Color. Dis. 2021, 23, 7–17. [Google Scholar] [CrossRef] [PubMed]
- Jain, D.; Berven, S. Effect of Obesity on the Development, Management, and Outcomes of Spinal Disorders. J. Am. Acad. Orthop. Surg. 2019, 27, e499–e506. [Google Scholar] [CrossRef]
- Leenen, L.P.H.; Kuypers, J.H.C. Some factors influencing the outcome of stoma surgery. Dis. Colon Rectum 1989, 32, 500–504. [Google Scholar] [CrossRef]
- Benoist, S.; Panis, Y.; Alves, A.; Valleur, P. Impact of obesity on surgical outcomes after colorectal resection. Am. J. Surg. 2000, 179, 275–281. [Google Scholar] [CrossRef] [PubMed]
- Reddy, J.G.; Loftus, E.V., Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol. Clin. N. Am. 2006, 35, 837–855. [Google Scholar] [CrossRef]
- Selvasekar, C.R.; Cima, R.R.; Larson, D.W.; Dozois, E.J.; Harrington, J.R.; Harmsen, W.S.; Loftus, E.V., Jr.; Sandborn, W.J.; Wolff, B.G.; Pemberton, J.H. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J. Am. Coll. Surg. 2007, 204, 956–962, discussion 962–953. [Google Scholar] [CrossRef] [PubMed]
- Ding, Z.; Wu, X.R.; Remer, E.M.; Lian, L.; Stocchi, L.; Li, Y.; McCullough, A.; Remzi, F.H.; Shen, B. Association between high visceral fat area and postoperative complications in patients with Crohn’s disease following primary surgery. Color. Dis. 2016, 18, 163–172. [Google Scholar] [CrossRef] [PubMed]
- Stidham, R.W.; Waljee, A.K.; Day, N.M.; Bergmans, C.L.; Zahn, K.M.; Higgins, P.D.; Wang, S.C.; Su, G.L. Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn’s disease. Inflamm. Bowel Dis. 2015, 21, 1306–1313. [Google Scholar] [CrossRef] [PubMed]
- Nauck, M.A.; Meier, J.J. Incretin hormones: Their role in health and disease. Diabetes Obes. Metab. 2018, 20 (Suppl. 1), 5–21. [Google Scholar] [CrossRef]
- Wang, J.-Y.; Wang, Q.-W.; Yang, X.-Y.; Yang, W.; Li, D.-R.; Jin, J.-Y.; Zhang, H.-C.; Zhang, X.-F. GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Front. Endocrinol. 2023, 14, 1085799. [Google Scholar] [CrossRef]
- Elangovan, A.; Shah, R.; Smith, Z.L. Pharmacotherapy for Obesity-Trends Using a Population Level National Database. Obes. Surg. 2021, 31, 1105–1112. [Google Scholar] [CrossRef]
- Villumsen, M.; Schelde, A.B.; Jimenez-Solem, E.; Jess, T.; Allin, K.H. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 2021, 37, 100979. [Google Scholar] [CrossRef]
- Chavda, V.P.; Ajabiya, J.; Teli, D.; Bojarska, J.; Apostolopoulos, V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules 2022, 27, 4315. [Google Scholar] [CrossRef] [PubMed]
- Jastreboff, A.M.; Aronne, L.J.; Ahmad, N.N.; Wharton, S.; Connery, L.; Alves, B.; Kiyosue, A.; Zhang, S.; Liu, B.; Bunck, M.C.; et al. Tirzepatide Once Weekly for the Treatment of Obesity. N. Engl. J. Med. 2022, 387, 205–216. [Google Scholar] [CrossRef] [PubMed]
- Krane, M.K.; Allaix, M.E.; Zoccali, M.; Umanskiy, K.; Rubin, M.A.; Villa, A.; Hurst, R.D.; Fichera, A. Does morbid obesity change outcomes after laparoscopic surgery for inflammatory bowel disease? Review of 626 consecutive cases. J. Am. Coll. Surg. 2013, 216, 986–996. [Google Scholar] [CrossRef] [PubMed]
- Lascano, C.A.; Soto, F.; Carrodeguas, L.; Szomstein, S.; Rosenthal, R.J.; Wexner, S.D. Management of ulcerative colitis in the morbidly obese patient: Is bariatric surgery indicated? Obes. Surg. 2006, 16, 783–786. [Google Scholar] [CrossRef] [PubMed]
- Keidar, A.; Hazan, D.; Sadot, E.; Kashtan, H.; Wasserberg, N. The role of bariatric surgery in morbidly obese patients with inflammatory bowel disease. Surg. Obes. Relat. Dis. 2015, 11, 132–136. [Google Scholar] [CrossRef] [PubMed]
- Tenorio Jimenez, C.; Manzano Garcia, G.; Prior Sanchez, I.; Corpas Jimenez, M.S.; Molina Puerta, M.J.; Benito Lopez, P. Bariatric surgery in inflammatory bowel disease; case report and review of the literature. Nutr. Hosp. 2013, 28, 958–960. [Google Scholar] [CrossRef]
- Moum, B.; Jahnsen, J. Obesity surgery in inflammatory bowel disease. Tidsskr. Nor. Laegeforen. 2010, 130, 638–639. [Google Scholar] [CrossRef]
- Bazerbachi, F.; Sawas, T.; Vargas, E.J.; Haffar, S.; Deepak, P.; Kisiel, J.B.; Loftus, E.V., Jr.; Abu Dayyeh, B.K. Bariatric Surgery Is Acceptably Safe in Obese Inflammatory Bowel Disease Patients: Analysis of the Nationwide Inpatient Sample. Obes. Surg. 2018, 28, 1007–1014. [Google Scholar] [CrossRef]
- Riss, S.; Schuster, I.; Papay, P.; Mittlbock, M.; Stift, A. Repeat intestinal resections increase the risk of recurrence of Crohn’s disease. Dis. Colon Rectum 2013, 56, 881–887. [Google Scholar] [CrossRef]
- Gould, J.; Ellsmere, J.; Fanelli, R.; Hutter, M.; Jones, S.; Pratt, J.; Schauer, P.; Schirmer, B.; Schwaitzberg, S.; Jones, D.B. Panel report: Best practices for the surgical treatment of obesity. Surg. Endosc. 2011, 25, 1730–1740. [Google Scholar] [CrossRef]
- Bilski, J.; Pinkas, M.; Wojcik-Grzybek, D.; Magierowski, M.; Korbut, E.; Mazur-Bialy, A.; Krzysiek-Maczka, G.; Kwiecien, S.; Magierowska, K.; Brzozowski, T. Role of Obesity, Physical Exercise, Adipose Tissue-Skeletal Muscle Crosstalk and Molecular Advances in Barrett’s Esophagus and Esophageal Adenocarcinoma. Int. J. Mol. Sci. 2022, 23, 3942. [Google Scholar] [CrossRef] [PubMed]
Study | Type of Study | Country | Year | Patient Characteristics (n; % Females) | Prevelance of Obesity | Median Follow-Up (Years) | Key Findings |
---|---|---|---|---|---|---|---|
Khalili et al. (2014) [21] | Population-based cohort study | USA | 1989 | CD: 153; 100% UC: 229; 100% | CD: 5.9% obese UC: 3% obese | 18 |
|
Jensen et al. (2018) [22] | Population-based cohort study | Denmark | 1977 | CD: 1500; 58% UC: 2732; 54% female | CD: 5% obese at age 13 UC: 5% obese at age 13 | 39 |
|
Chan et al. (2013) [23] | Prospective cohort study | Denmark Germany Netherlands Italy Sweden United Kingdom | 1991–1998 | CD: 75; 54% UC: 177; 64% | CD: 9% obese UC: 12% obese | 5 |
|
He et al. (2023) [24] | Prospective cohort study | United Kingdom | 2006–2010 | CD: 915, 56.4% UC: 2039, 47.1% | N/A | 12.5 |
|
Harpsøe et al. (2015) [25] | Population-based cohort study | Denmark | CD: 138, 100% UC: 394, 100% | 8.1% obese | 11 |
| |
Pringle et al. (2015) [26] | Cross-sectional study | USA | 2004 | CD: 846, 55% | 16% obese | 12 |
|
Hass et al. (2006) [27] | Retrospective cohort study | USA | 1997–2002 | CD: 138, 59% | 32% obese | 13 |
|
Seminerio et al. (2015) [19] | Retrospective cohort study | USA | 2009–2011 | CD: 860, 51% UC: 634, 51% | 31.5% obese | N/A |
|
Flores et al. (2015) [18] | Retrospective cohort study | USA | 2000–2012 | CD: 297, 31% UC: 284, 24% | CD: 30.3% obese UC: 35.2% obese | 5.2 |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kaazan, P.; Seow, W.; Yong, S.; Heilbronn, L.K.; Segal, J.P. The Impact of Obesity on Inflammatory Bowel Disease. Biomedicines 2023, 11, 3256. https://doi.org/10.3390/biomedicines11123256
Kaazan P, Seow W, Yong S, Heilbronn LK, Segal JP. The Impact of Obesity on Inflammatory Bowel Disease. Biomedicines. 2023; 11(12):3256. https://doi.org/10.3390/biomedicines11123256
Chicago/Turabian StyleKaazan, Patricia, Warren Seow, Shaanan Yong, Leonie K. Heilbronn, and Jonathan P. Segal. 2023. "The Impact of Obesity on Inflammatory Bowel Disease" Biomedicines 11, no. 12: 3256. https://doi.org/10.3390/biomedicines11123256